BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 30151560)

  • 1. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium.
    Groen JV; Sibinga Mulder BG; van Eycken E; Valerianova Z; Borras JM; van der Geest LGM; Capretti G; Schlesinger-Raab A; Primic-Zakelj M; Ryzhov A; van de Velde CJH; Bonsing BA; Bastiaannet E; Mieog JSD
    Ann Surg Oncol; 2018 Nov; 25(12):3492-3501. PubMed ID: 30151560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall survival is increased among stage III pancreatic adenocarcinoma patients receiving neoadjuvant chemotherapy compared to surgery first and adjuvant chemotherapy: An intention to treat analysis of the National Cancer Database.
    Shubert CR; Bergquist JR; Groeschl RT; Habermann EB; Wilson PM; Truty MJ; Smoot RL; Kendrick ML; Nagorney DM; Farnell MB
    Surgery; 2016 Oct; 160(4):1080-1096. PubMed ID: 27522556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.
    Picozzi VJ; Oh SY; Edwards A; Mandelson MT; Dorer R; Rocha FG; Alseidi A; Biehl T; Traverso LW; Helton WS; Kozarek RA
    Ann Surg Oncol; 2017 Jun; 24(6):1722-1730. PubMed ID: 28054192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of lymph node positivity in treatment planning for early stage pancreatic cancer.
    Tran Cao HS; Zhang Q; Sada YH; Silberfein EJ; Hsu C; Van Buren G; Chai C; Katz MHG; Fisher WE; Massarweh NN
    Surgery; 2017 Sep; 162(3):557-567. PubMed ID: 28666686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival.
    Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
    Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer.
    Mirkin KA; Greenleaf EK; Hollenbeak CS; Wong J
    Cancer; 2016 Oct; 122(19):2979-87. PubMed ID: 27328270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
    de Geus SW; Eskander MF; Bliss LA; Kasumova GG; Ng SC; Callery MP; Tseng JF
    Surgery; 2017 Mar; 161(3):592-601. PubMed ID: 28341441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-agent neoadjuvant chemotherapy improves survival in early-stage pancreatic cancer: A National Cancer Database analysis.
    Deng A; Wang C; Cohen SJ; Winter JM; Posey J; Yeo C; Basu Mallick A
    Eur J Cancer; 2021 Apr; 147():17-28. PubMed ID: 33607382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative analysis of survival outcomes between pancreatectomy and chemotherapy for elderly patients with adenocarcinoma of the pancreas.
    Marmor S; Burke EE; Virnig BA; Jensen EH; Tuttle TM
    Cancer; 2016 Nov; 122(21):3378-3385. PubMed ID: 27419382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal pancreatectomies.
    Nassour I; Adam MA; Kowalsky S; Al Masri S; Bahary N; Singhi AD; Lee K; Zureikat A; Paniccia A
    J Surg Oncol; 2021 Jan; 123(1):245-251. PubMed ID: 33103242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External radiation is associated with limited improvement in overall survival in resected margin-negative stage IIB pancreatic adenocarcinoma.
    Kantor O; Talamonti MS; Lutfi W; Wang CH; Winchester DJ; Marsh R; Prinz RA; Baker MS
    Surgery; 2016 Dec; 160(6):1466-1476. PubMed ID: 27614417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma.
    Ocuin LM; Hardacre JM; Ammori JB; Rothermel LD; Mohamed A; Selfridge JE; Bajor D; Winter JM
    J Surg Oncol; 2020 Dec; 122(8):1595-1603. PubMed ID: 32844445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
    Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
    Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond the dollar: Influence of sociodemographic marginalization on surgical resection, adjuvant therapy, and survival in patients with pancreatic cancer.
    Kagedan DJ; Abraham L; Goyert N; Li Q; Paszat LF; Kiss A; Earle CC; Mittmann N; Coburn NG
    Cancer; 2016 Oct; 122(20):3175-3182. PubMed ID: 27391466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional targeting chemoimmunotherapy in patients undergoing pancreatic resection in an advanced stage of their disease: a prospective randomized study.
    Lygidakis NJ; Sgourakis G; Georgia D; Vlachos L; Raptis S
    Ann Surg; 2002 Dec; 236(6):806-13. PubMed ID: 12454519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant therapy in operable pancreatic cancer.
    Wente MN; Büchler P; Friess H; Büchler MW
    Swiss Surg; 2002; 8(2):74-80. PubMed ID: 12013694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review.
    Attard JA; Farrugia A; Pathanki A; Roberts KJ; Dasari B; Isaac J; Ma YT; Chatzizacharias NA
    Pancreas; 2020; 49(10):1264-1275. PubMed ID: 33122513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes - an American College of Surgeons National Surgical Quality Improvement Program targeted variable review.
    Czosnyka NM; Borgert AJ; Smith TJ
    HPB (Oxford); 2017 Oct; 19(10):927-932. PubMed ID: 28747265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.